Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The main aim of this trial is to evaluate whether additional acupuncture or mindfulness-based stress reduction is more efficacious than usual care only to reduce fatigue in patients with multiple sclerosis.
In multiple sclerosis, fatigue is the most common clinical symptom, reported by up to 97% of patients. No successful evidence-based therapy exists so far. The main aim of this trial is to evaluate whether additional acupuncture or mindfulness-based stress reduction is more efficacious than usual care only to reduce fatigue in patients with multiple sclerosis. We want to include 141 patients with multiple sclerosis and fatigue. Participants will be randomised into three groups to compare 1) usual care, 2) usual care plus standardised acupuncture, and 3) usual care plus mindfulness-based stress reduction. Treatment duration will be 12 weeks. The primary outcome is the Fatigue Severity Scale (FSS) after 12 weeks, follow-up measurement will be performed after 26 weeks. Secondary outcomes include other fatigue specific parameters, other MS specific parameters, cost, and physiological, immunological and functional magnetic resonance imaging parameters.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| usual care + acupuncture | Experimental | standardized acupuncture treatment in addition to usual care |
|
| usual care+mbsr | Experimental | mindfulness based stress reduction in addition to usual care not recruiting anymore |
|
| usual care | Active Comparator | usual care without additional treatment |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Usual care + acupuncture | Other | Patients of this group receive a standardized acupuncture treatment over 12 weeks in addition to usual care |
|
| Measure | Description | Time Frame |
|---|---|---|
| fatigue severity scale | 12 weeks |
| Measure | Description | Time Frame |
|---|---|---|
| fatigue severity scale | 26 weeks | |
| modified fatigue impact scale | baseline, 8 weeks, 26 weeks | |
| therapy response rates |
| Measure | Description | Time Frame |
|---|---|---|
| fMRI | e.g. functional connectivity in a subgroup of 20 subjects in each group | baseline, 12 weeks, 26 weeks |
| Dynamics of saccade parameters | Eye movement analysis will be performed according established standards (Finke et al, J Neurol 2012) |
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Claudia M Witt, MD | Institute for Social Medicine, Epidemiology and Health Economics, Charité - Universitätsmedizin Berlin | Principal Investigator |
| Friedemann Paul, MD | The NeuroCure Clinical Research Center, Charité - Universitätsmedizin Berlin | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| The NeuroCure Clinical Research Center, Charité - Universitätsmedizin Berlin | Berlin | State of Berlin | 10117 | Germany |
Not provided
| ID | Term |
|---|---|
| D005221 | Fatigue |
| D009103 | Multiple Sclerosis |
| ID | Term |
|---|---|
| D012816 | Signs and Symptoms |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D020278 | Demyelinating Autoimmune Diseases, CNS |
| D020274 | Autoimmune Diseases of the Nervous System |
Not provided
Not provided
| ID | Term |
|---|---|
| D015670 | Acupuncture Therapy |
| ID | Term |
|---|---|
| D000529 | Complementary Therapies |
| D013812 | Therapeutics |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| usual care+mbsr | Other | Patients of this group receive mindfulness based stress reduction in addition to usual care |
|
| usual care | Other | Patients in this group will follow the same treatment for fatigue they received at study entry |
|
| 12 weeks |
| expanded disability status scale | baseline, 12 weeks, 26 weeks |
| multipe sclerosis functional composite scale | baseline, 12 weeks, 26 weeks |
| beck depression inventory II | baseline, 12 weeks, 26 weeks |
| Body efficacy expectation | Body-Efficacy Expectation (BEE) is a scale to measure the conviction that one's body is able to deal with health-threatening factors by itself. It is a six items' scale developed in the Institute of Social Medicine, Epidemiology and Health Economics and not published, yet. | baseline, 12 weeks, 26 weeks |
| SF-12 | baseline, 12 weeks, 26 weeks |
| HAQUAMS | baseline, 12 weeks, 26 weeks |
| Costs | Data on Resource-consumption and associated costs are planned to be derived as patient-reported information using the patient questionnaires. | baseline, 12 weeks, 26 weeks |
| overall treatment effect | 12 weeks, 26 weeks |
| immune parameters | PBMC and proliferationsassays, pro- and antiinflamatory cytokines, axonal damage marker such as neurofilaments and neurotrophic factors like BDNF possible influences on the immune system will be evaluated in an exploratory way. | baseline, 12 weeks, 26 weeks |
| number of serious adverse events | 12 weeks, 26 weeks |
| number of suspected adverse reactions | 12 weeks, 26 weeks |
| baseline, 12 weeks, 26 weeks, and directly after one acupuncture session |
| Qualitative interviews regarding therapy | Part of the patients will be interviewed about the therapies. | 26 weeks |
| D009422 | Nervous System Diseases |
| D003711 | Demyelinating Diseases |
| D001327 | Autoimmune Diseases |
| D007154 | Immune System Diseases |